Deutsche Bank reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a report published on Thursday. They currently have a GBX 5,700 ($77.30) price target on the biopharmaceutical company’s stock.
Other research analysts have also issued research reports about the company. Investec lifted their price target on AstraZeneca from GBX 4,900 ($66.45) to GBX 5,500 ($74.59) and gave the stock a buy rating in a research report on Monday, November 6th. Citigroup reaffirmed a buy rating and set a GBX 6,000 ($81.37) price target on shares of AstraZeneca in a research report on Wednesday. Barclays set a GBX 6,300 ($85.44) price target on AstraZeneca and gave the stock a buy rating in a research report on Wednesday, September 13th. Berenberg Bank set a GBX 5,800 ($78.65) price target on AstraZeneca and gave the stock a buy rating in a research report on Tuesday, September 19th. Finally, Jefferies Group reaffirmed a hold rating and set a GBX 5,100 ($69.16) price target on shares of AstraZeneca in a research report on Monday, November 6th. Four analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company. AstraZeneca currently has an average rating of Hold and a consensus price target of GBX 5,200.82 ($70.53).
AstraZeneca (AZN) remained flat at $GBX 5,132 ($69.60) on Thursday. The company had a trading volume of 1,835,225 shares, compared to its average volume of 1,720,000. The company has a market cap of $64,820.00 and a price-to-earnings ratio of 2,479.23. AstraZeneca has a 1 year low of GBX 4,136.50 ($56.10) and a 1 year high of GBX 5,520 ($74.86).
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.